Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ancient herbs take on stubborn heart pain in seniors

NCT ID NCT07041359

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times

Summary

This study tests whether two traditional Chinese medicines—Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills—can reduce chest pain and improve quality of life in elderly patients (75-90 years old) with coronary heart disease who still have symptoms despite standard treatment. 120 participants will receive either one of the herbal pills or a placebo, alongside their usual medications. The goal is to see if these herbs safely ease symptoms like angina and shortness of breath.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERIAL DISEASE (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fuwai hospital, CAMS&PUMC

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills

What this could lead to

If successful, this could provide a safe add-on option to reduce angina symptoms and improve daily life for elderly heart disease patients who still have symptoms despite standard treatment.

What could go wrong

This is a small, early-phase trial (120 participants) focused on symptom relief, not a cure. The benefits may be modest, and results may not apply to all patients. Risks include potential herb-drug interactions.

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.